Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Fiche publication
Date publication
avril 2016
Journal
Urologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM,
Lien Pubmed
Résumé
Glandular metastases (GMs) (pancreas, breast, parotid, thyroid, or contralateral adrenal) are rare in metastatic clear cell renal cell carcinoma (mccRCC). In a multicenter study we have assessed outcome from mccRCC with or without GMs.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, therapeutic use, Carcinoma, Renal Cell, drug therapy, Female, Humans, Kidney Neoplasms, drug therapy, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Survival Rate, Young Adult
Référence
Urol. Oncol.. 2016 Apr;34(4):167.e17-23